GlassScriptPhysician profile
Andrew D Feingold
NPI 1528090727
$443.99
in general payments reported to CMS, 2019-2025
9 companies · $196 in 2025
The $196 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.81 · 2021: $81.65 · 2022: $11.64 · 2023: $26.84 · 2024: $111 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $333.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $120.72 | 2024-2025 | Wainua |
| Pfizer INC. | $101.08 | 2025 | |
| Abbott Laboratories | $70.20 | 2020-2021 | |
| Amgen INC. | $36.53 | 2024-2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.26 | 2021 | |
| Alnylam Pharmaceuticals INC. | $26.84 | 2023 | Onpattro |
| Novartis Pharmaceuticals Corporation | $26.71 | 2024 | |
| Novo Nordisk INC | $22.01 | 2024 | Ozempic |
| Biotronik INC. | $11.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Feingold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.